Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tariff System (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Jaypirca (pirtobrutinib) for the treatment of patients with B-cell lymphomas
- Jaypirca (pirtobrutinib) for the treatment of patients with chronic lymphocytic leukemia
- Nubeqa (darolutamide) for the treatment of patients with prostate cancer
- Ramizek Plus (ramipril + bisoprolol fumarate) for the treatment of hypertension
- Ramizek Plus (ramipril + bisoprolol fumarate) for the treatment of chronic coronary syndrome
- Ladinorm (ramipril + bisoprolol fumarate) for all registered indications as of the date of the decision
- Efluelda, trivalent influenza vaccine (split virion)
- Braftovi (encorafenib) for the treatment of patients with colorectal cancer
- Vaxigrip, trivalent influenza vaccine
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
